These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 25494980

  • 1. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A, Brossa A, Bernardini M, Genova T, Grolez G, Villers A, Leroy X, Prevarskaya N, Gkika D, Bussolati B.
    BMC Cancer; 2014 Dec 12; 14():939. PubMed ID: 25494980
    [Abstract] [Full Text] [Related]

  • 2. Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
    Denorme M, Yon L, Roux C, Gonzalez BJ, Baudin E, Anouar Y, Dubessy C.
    Cancer Lett; 2014 Oct 01; 352(2):236-44. PubMed ID: 25016061
    [Abstract] [Full Text] [Related]

  • 3. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R, Damiano V, Nappi L, Formisano L, Massari F, Scarpa A, Martignoni G, Bianco R, Tortora G.
    Br J Cancer; 2013 Aug 06; 109(3):686-93. PubMed ID: 23839492
    [Abstract] [Full Text] [Related]

  • 4. Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
    Nakai Y, Miyake M, Morizawa Y, Hori S, Tatsumi Y, Anai S, Onishi S, Tanaka N, Fujimoto K.
    Oncol Rep; 2017 Jan 06; 37(1):227-234. PubMed ID: 27840968
    [Abstract] [Full Text] [Related]

  • 5. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
    Serova M, de Gramont A, Tijeras-Raballand A, Dos Santos C, Riveiro ME, Slimane K, Faivre S, Raymond E.
    Cancer Chemother Pharmacol; 2013 May 06; 71(5):1297-307. PubMed ID: 23479136
    [Abstract] [Full Text] [Related]

  • 6. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
    Yu P, Ye L, Wang H, Du G, Zhang J, Zuo Y, Zhang J, Tian J.
    PLoS One; 2014 May 06; 9(12):e115041. PubMed ID: 25551444
    [Abstract] [Full Text] [Related]

  • 7. Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
    Yildiz C, Kacan T, Akkar OB, Karakus S, Kacan SB, Ozer H, Cetin A.
    Reprod Sci; 2015 Nov 06; 22(11):1445-51. PubMed ID: 25963915
    [Abstract] [Full Text] [Related]

  • 8. Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
    Elsner A, Lange F, Fitzner B, Heuschkel M, Krause BJ, Jaster R.
    World J Gastroenterol; 2014 Jun 28; 20(24):7914-25. PubMed ID: 24976727
    [Abstract] [Full Text] [Related]

  • 9. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
    Martin B, Edeline J, Patard JJ, Oger E, Jouan F, Boulanger G, Zerrouki S, Vigneau C, Rioux-Leclercq N.
    J Cancer Res Clin Oncol; 2012 Jun 28; 138(6):907-16. PubMed ID: 22322364
    [Abstract] [Full Text] [Related]

  • 10. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep 28; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 11. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
    Ou DL, Lee BS, Chang YC, Lin LI, Liou JY, Hsu C, Cheng AL.
    PLoS One; 2013 Sep 28; 8(6):e66589. PubMed ID: 23818948
    [Abstract] [Full Text] [Related]

  • 12. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Juengel E, Kim D, Makarević J, Reiter M, Tsaur I, Bartsch G, Haferkamp A, Blaheta RA.
    J Cell Mol Med; 2015 Feb 28; 19(2):430-41. PubMed ID: 25444514
    [Abstract] [Full Text] [Related]

  • 13. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Kancha RK, Grundler R, Peschel C, Duyster J.
    Exp Hematol; 2007 Oct 28; 35(10):1522-6. PubMed ID: 17889720
    [Abstract] [Full Text] [Related]

  • 14. Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
    Laurila JP, Laukkanen MO, Joensuu H, Salmi M, Jalkanen S.
    Int J Cancer; 2016 Nov 15; 139(10):2270-6. PubMed ID: 27459381
    [Abstract] [Full Text] [Related]

  • 15. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
    Kumar R, Crouthamel MC, Rominger DH, Gontarek RR, Tummino PJ, Levin RA, King AG.
    Br J Cancer; 2009 Nov 17; 101(10):1717-23. PubMed ID: 19844230
    [Abstract] [Full Text] [Related]

  • 16. Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O: rapid inhibition of Rb phosphorylation as a preamble to cyclin D1 inhibition.
    Debata PR, Begum S, Mata A, Genzer O, Kleiner MJ, Banerjee P, Castellanos MR.
    Anticancer Agents Med Chem; 2013 Dec 17; 13(10):1508-13. PubMed ID: 23848205
    [Abstract] [Full Text] [Related]

  • 17. Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment.
    Hatipoglu G, Hock SW, Weiss R, Fan Z, Sehm T, Ghoochani A, Buchfelder M, Savaskan NE, Eyüpoglu IY.
    Cancer Sci; 2015 Feb 17; 106(2):160-70. PubMed ID: 25458015
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
    Sulkes A.
    Isr Med Assoc J; 2010 Oct 17; 12(10):628-32. PubMed ID: 21090521
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.